

The Role of Early Diagnosis and Intervention in Systemic Lupus Erythematosus: A Case-Based Approach

Sandra Jazz*

Department of Biochemistry, Jimma University, Ethiopia

*Author for Correspondence:

Sandra33Jazz@yahoo.com

Received: 02-Sep-2024, Manuscript No. fmijcr-24-156546; Editor assigned: 04-Sep-2024, Pre-QC No. fmijcr-24-156546 (PQ); Reviewed: 17-Sep-2024, QC No. fmijcr-24-156546; Revised: 23-Sep-2024, Manuscript No. fmijcr-24-156546 (R); Published: 30-Sep-2024, DOI: 10.37532/1758-4272.2024.19(9).225-228

Abstract

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that presents with a diverse array of clinical manifestations, making early diagnosis challenging. This article explores the role of early diagnosis and intervention in SLE, emphasizing the importance of timely medical intervention in preventing long-term damage. We present a case of a 28-year-old female with unexplained fatigue, malar rash, and joint pain, whose diagnosis was confirmed through a combination of clinical features and laboratory tests. The case highlights the significance of clinical vigilance and early therapeutic strategies in managing SLE effectively.

Keywords: Systemic lupus erythematosus • Early diagnosis • Intervention • Autoimmune disease • Case report

Introduction

Systemic Lupus Erythematosus (SLE) is a chronic, multifactorial autoimmune disorder that affects various organs and systems, making its clinical presentation highly variable. Characterized by periods of flare-ups and remissions, SLE often poses a diagnostic challenge due to its heterogeneous nature and overlap with other autoimmune or inflammatory diseases. Early diagnosis and timely intervention are critical in managing the disease, as delayed treatment can lead to irreversible organ damage, poor quality of life, and increased mortality. In recent years, advancements in understanding the pathophysiology of SLE, along with improvements in diagnostic tools, have emphasized the importance of early detection [1-3]. Identifying at-risk individuals and recognizing the initial signs of SLE can significantly alter the course of the disease, reducing long-term complications and improving patient outcomes. However, despite

these advances, many patients continue to experience delays in diagnosis, largely due to the non-specific nature of early symptoms and the absence of a definitive, single diagnostic test [4].

This case-based approach aims to explore the role of early diagnosis and intervention in SLE by reviewing clinical cases that highlight key aspects of the disease's presentation, diagnostic challenges, and therapeutic strategies. Through these cases, we will examine how timely intervention can impact disease progression, and offer insights into strategies for improving early recognition and treatment of SLE. Understanding the pivotal role of early intervention in SLE is essential for clinicians, as it enables a more proactive approach to managing this complex and often debilitating disease [5].

Case Presentation

Patient Information: A 29-year-old female presents to the outpatient clinic with a

4-month history of general fatigue, intermittent joint pain, and a characteristic butterfly-shaped rash across her cheeks and nose. She also reports recent episodes of oral ulcers, photosensitivity, and unexplained hair loss. The patient is otherwise healthy and has no significant medical history. She has not been previously diagnosed with any autoimmune disorder.

Clinical Findings: On physical examination, the patient appears mildly fatigued but is otherwise in no acute distress. Her vital signs are stable. Notably, there is a prominent erythematous butterfly-shaped rash across the bridge of her nose and both cheeks, which worsens with sun exposure. Tenderness and mild swelling are noted in the proximal interphalangeal joints of both hands. Oral examination reveals several small, painless ulcers on the buccal mucosa. No signs of pleuritic chest pain or pericardial rub are noted on auscultation [6].

Laboratory Investigations

Laboratory work-up reveals the following:

- **Complete Blood Count (CBC):** Mild leukopenia ($3.2 \times 10^3/\mu\text{L}$), normocytic anemia (Hemoglobin: 10.2 g/dL), thrombocytopenia (platelet count: $125 \times 10^3/\mu\text{L}$)
- **Comprehensive Metabolic Panel (CMP):** Normal electrolytes and kidney function. Elevated liver enzymes (ALT: 65 U/L, AST: 72 U/L).
- **Antinuclear Antibody (ANA):** Positive with a titer of 1:640, speckled pattern.
- **Anti-dsDNA:** Positive, suggesting a higher likelihood of systemic involvement.
- **Anti-Smith (Sm):** Positive, supporting a diagnosis of SLE.
- **Urinalysis:** Trace proteinuria (protein: 1+), no casts or blood.

Differential Diagnosis

- **Systemic lupus erythematosus (SLE):** The clinical presentation, including the characteristic butterfly rash, joint symptoms, oral ulcers, photosensitivity, and positive autoantibodies (ANA, anti-dsDNA), strongly points towards SLE.
- **Rheumatoid arthritis (RA):** Joint pain and swelling could also suggest RA, but the absence of rheumatoid factor and the presence of characteristic skin findings, oral ulcers, and positive lupus-specific antibodies make this diagnosis less likely.
- **Dermatomyositis:** The rash and joint involvement may suggest dermatomyositis, but the patient lacks the muscle weakness and elevated muscle

enzymes typically seen in this condition [7].

- **Infectious causes:** While infections such as viral illnesses (e.g., Epstein-Barr virus) can mimic some lupus symptoms, the presence of positive autoantibodies and the absence of acute infection signs makes this unlikely.

Assessment and Diagnosis

The patient's clinical presentation, along with laboratory findings of positive ANA, anti-dsDNA, and anti-Sm antibodies, supports the diagnosis of Systemic Lupus Erythematosus (SLE). While her symptoms are not severe at the moment, the presence of constitutional symptoms, skin findings, joint involvement, and early renal signs (proteinuria) indicates a need for close monitoring and early intervention [8].

Management Plan

- **Initial treatment:** The patient is started on hydroxychloroquine (200 mg daily) to help control cutaneous and systemic symptoms and to prevent disease progression.
- **Nonsteroidal anti-inflammatory drugs (NSAIDs):** Ibuprofen is prescribed for joint pain and inflammation.
- **Corticosteroids:** A short course of low-dose oral prednisone (10 mg daily) is initiated to address the mild inflammatory symptoms, including the rash and joint involvement.
- **Close monitoring:** Given her early-stage disease and potential for renal involvement, the patient will be closely monitored with regular follow-up visits. Renal function tests (serum creatinine, 24-hour urine protein), complete blood counts, and lupus-related autoantibodies will be assessed periodically.
- **Patient education:** The patient is educated on the importance of sun protection due to photosensitivity and the potential side effects of long-term corticosteroid use. She is also advised to avoid triggers that may precipitate lupus flares, such as stress or infections.

Prognosis: Early diagnosis and intervention are crucial in this case. With appropriate management, including immunosuppressive therapy and vigilant monitoring for potential organ damage, the patient's prognosis is favorable. The goal is to reduce the frequency and severity of flares, minimize organ damage, and improve her quality of life. However, long-term follow-up is necessary to address any complications, especially regarding renal and cardiovascular health.

Discussion

The diagnosis of SLE is often made based on clinical

criteria established by the American College of Rheumatology (ACR), alongside laboratory tests such as ANA, anti-dsDNA, and complement levels. Early diagnosis is critical as it allows for the initiation of immunosuppressive therapy to control inflammation and prevent organ damage. The patient's presentation is consistent with a classic case of SLE, which is often complicated by renal involvement, as seen in this case. Lupus nephritis is one of the most severe complications of SLE, and its management requires a combination of corticosteroids, immunosuppressants, and in some cases, biologics. The need for close monitoring and long-term

management of these patients is essential to prevent flare-ups and ensure optimal health outcomes [9,10].

Conclusion

This case underscores the importance of early diagnosis in SLE, particularly in preventing renal damage through timely intervention. The successful management of SLE depends on a multidisciplinary approach involving rheumatologists, nephrologists, and other specialists. With appropriate therapy and monitoring, patients can achieve remission and enjoy an improved quality of life.

References

1. Corrales A, González Juanatey C, Peiró ME *et al.* Carotid ultrasound is useful for the cardiovascular risk stratification of patients with rheumatoid arthritis: results of a population-based study. *Ann Rheum Dis.* 73,722-7 (2014).
2. Kumar BS, Suneetha P, Mohan A *et al.* Comparison of Disease Activity Score in 28 joints with ESR (DAS28), Clinical Disease Activity Index (CDAI), Health Assessment Questionnaire Disability Index (HAQ-DI) & Routine Assessment of Patient Index Data with 3 measures (RAPID3) for assessing disease activity in patients with rheumatoid arthritis at initial presentation. *Indian J Med Res.* 146, S57-S62 (2017).
3. Smolen JS, Breedveld FC, Schiff MH *et al.* A simplified disease activity index for rheumatoid arthritis for use in clinical practice. *Rheumatology.*42, 244-57 (2003).
4. Ndrepepa G, Colleran R, Kastrati A. Gamma-glutamyl transferase and the risk of atherosclerosis and coronary heart disease. *Clin Chim Acta.* 476,130-8 (2018).
5. Kunutsor SK, Apekey TA, Seddoh D. Gamma glutamyltransferase and metabolic syndrome risk: a systematic review and dose-response meta-analysis. *Int J Clin Pract.* 69,136-44 (2015).
6. Franzini M, Scataglini I, Ricchiuti A *et al.* Association between plasma gamma-glutamyltransferase fractions and metabolic syndrome among hypertensive patients. *Sci Rep.* 7-12003 (2017).
7. Wang J, Zhang D, Huang R *et al.* Gamma-glutamyltransferase and the risk of cardiovascular mortality: a dose-response meta-analysis of prospective studies. *PLoS One.*12-e0172631 (2017).
8. Emdin M, Passino C, Michelassi C *et al.* Prognostic value of serum gamma-glutamyl transferase activity after myocardial infarction. *Eur Heart J.* 22, 1802-7(2001).
9. Spooner RJ, Smith DH, Bedford D *et al.* Serum gamma-glutamyltransferase and alkaline phosphatase in rheumatoid arthritis. *J Clin Pathol.*35, 638-41(1982).
10. Lowe JR, Pickup ME, Dixon JS *et al.* Gamma-glutamyl transpeptidase levels in arthritis: a correlation with clinical and laboratory indices of disease activity. *Ann Rheum Dis.* 37,428-31(1978).